타이틀

IR/PRASCO 2018: YH25448, a 3 rd Generation EGFR TKI, in Patients with EGFR TKI resistant NSCLC: Phase I/II Study Results

IR/PRAACR 2018: YH25448, an irreversible 3rd-generation EGFR TKI, exhibits superior anticancer effects with potent brain BBB penetration in NSCLC

IR/PRCancer Research: Superior Efficacy and Selectivity of Novel Small-Molecule Kinase Inhibitors of T790M-Mutant EGFR in Preclinical Models of Lung Cancer

IR/PRIASLC 2016: YH25448, a highly selective 3rd generation EGFR TKI, exhibits superior survival benefit over osimertinib in mice with brain metastases of NSCLC

IR/PRCrystal structures of spleen tyrosine kinase in complex with novel inhibitors: structural insights for design of anticancer drugs

IR/PRHighly potent and selective pyrazolylpyrimidines as Syk kinase inhibitors